Beyond prognosis, our data reveal ALDOA’s central role in driving tumor progression through metabolic reprogramming, macrophage-mediated immune suppression, and therapy resistance, positioning it as a multi-faceted therapeutic node [45, 55]. The gene discussed is ALDOA; the disease is neoplasm.